This company has been marked as potentially delisted and may not be actively trading. NASDAQ:QTNT Quotient (QTNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Quotient Stock (NASDAQ:QTNT) 30 days 90 days 365 days Advanced Chart Get Quotient alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.19▼$0.8052-Week Range N/AVolume5.81 million shsAverage Volume437,886 shsMarket Capitalization$980,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewQuotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.Read More… Receive QTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quotient and its competitors with MarketBeat's FREE daily newsletter. Email Address QTNT Stock News HeadlinesQuotient (NASDAQ: QTNT)September 5, 2023 | fool.comQuotient Second Quarter 2023 Earnings: Revenues Miss ExpectationsNovember 16, 2022 | finance.yahoo.comThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.June 3, 2025 | Altimetry (Ad)Quotient Limited Announces Reverse Stock Split Effective TodayNovember 2, 2022 | finance.yahoo.comGlobalFair secures new cash to simplify procuring construction materials - TechCrunchOctober 20, 2022 | techcrunch.comTransforming Uncertainty Into Possibility - ForbesOctober 19, 2022 | forbes.comQuotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility - BenzingaOctober 18, 2022 | benzinga.comH.I.G. Acquisition Corp. Announces Redemption of Class A Ordinary Shares - Yahoo FinanceOctober 15, 2022 | finance.yahoo.comSee More Headlines QTNT Stock Analysis - Frequently Asked Questions How were Quotient's earnings last quarter? Quotient Limited (NASDAQ:QTNT) issued its quarterly earnings results on Thursday, August, 5th. The company reported ($9.60) earnings per share for the quarter, beating the consensus estimate of ($10.40) by $0.80. The company earned $9.09 million during the quarter, compared to analyst estimates of $9.10 million. When did Quotient's stock split? Quotient shares reverse split on the morning of Thursday, November 3rd 2022. The 1-40 reverse split was announced on Thursday, November 3rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Quotient own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quotient investors own include Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F), Wayfair (W), Zomedica (ZOM), Wells Fargo & Company (WFC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/05/2021Today6/03/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:QTNT CIK1596946 Webwww.quotientbd.com Phone(122) 716-9800FaxN/AEmployees426Year Founded2008Profitability EPS (Most Recent Fiscal Year)($53.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$125.13 million Net Margins-413.55% Pretax Margin-411.03% Return on EquityN/A Return on Assets-88.21% Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio1.36 Sales & Book Value Annual Sales$38.51 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($56.17) per share Price / BookN/AMiscellaneous Outstanding Shares2,580,000Free Float2,309,000Market Cap$980,000.00 OptionableOptionable Beta2.32 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:QTNT) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quotient Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Quotient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.